tbuckley/cabot-search huggingface dataset:
Abstract 716: 3-D imaging and illustration of nerve-lesion association in the mouse tongue of experimental oral cancer.
Authors: Tzu-En Hua, Ko-Jiunn Liu, Shiue-Cheng Tang
Journal: Cancer Research (2013)

Abstract Introduction: Tongue has a rich nerve supply and is in constant contact with a variety of neurotrophins in the saliva. In tongue/oral cancer, patients suffer from pain that is often more severe than the symptom caused by other cancers, likely due to the stimulation of the nerve endings and/or compression and invasion of sensory nerves. Despite the noticeable neural component in tongue/oral cancer development, high-resolution microscopic observation of the tongue innervation in health and disease has been difficult. This is primarily due to the dispersed neural network in space that cannot be easily portrayed by the standard microtome-based 2-dimensional (2-D) microscopy. The artifact and distortion caused by microtome slicing as well as the challenge of aligning series of microtome slices in precision seriously limit our ability to examine tongue innervation. Method: To overcome the imaging limitation, we prepared transparent mouse tongue specimens by optical clearing (use of immersion solution to reduce random scattering as light travels across media; Fu &amp; Tang, Gastroenterology, 139:p1100, 2010 and www.3d-histology.com) and combined vessel painting and 3-dimensional (3-D) neurohistology for joint visualization of the tongue tissue architectures. Cardiac perfusion of the fluorescent lectin was used to label the blood vessels. Neuronal markers including PGP9.5, tyrosine hydroxylase, vesicular acetylcholine transporter, and calcitonin gene-related peptide were used as the immunostaining targets of neural tissues. Results: We simultaneously revealed the microstructure, vasculature, and innervation of the normal tongue with μm-level resolution. Examples of 3-D features such as the neurovascular complex at the core of the filiform papilla and the taste bud innervation in the fungiform papilla were used to demonstrate the image quality. In the progression of experimental oral cancer induced by 4-Nitroquinoline-1-oxide, we observed remodeling of the tongue innervation with prominent peri- or intra-lesional nerve fibers, indicating intimate nerve-lesion interactions. Sympathetic, parasympathetic, and sensory nerves were all found associated with the lesion. Conclusion: This tongue innervation imaging method does not require tissue microtome sectioning and provides a useful tool for 3-D presentation and analysis of normal and diseased tongue in an integrated fashion. Citation Format: Tzu-En Hua, Ko-Jiunn Liu, Shiue-Cheng Tang. 3-D imaging and illustration of nerve-lesion association in the mouse tongue of experimental oral cancer. [abstract]. In: Proceedings of the 104th Annual Meeting of the American Association for Cancer Research; 2013 Apr 6-10; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2013;73(8 Suppl):Abstract nr 716. doi:10.1158/1538-7445.AM2013-716
Abstract 2968: The functional relationship between CHFR and PARP-1 controls the antephase checkpoint and tumor development
Authors: Lisa Kashima, Hiroaki Mita, Masashi Idogawa, Minoru Toyota, Yasushi Sasaki, Takashi Tokino
Journal: Cancer Research (2011)

Abstract The mitotic checkpoint gene CHFR is silenced by promoter hypermethylation or mutated in various human cancers, suggesting that CHFR is an important tumor suppressor. Recent studies have reported that CHFR functions as an E3 ubiquitin ligase of Aurora A and HDAC1, resulting in the degradation of those proteins. To better understand how CHFR suppresses cell cycle progression and tumorigenesis, we sought to identify CHFR-interacting proteins using affinity purification combined with mass spectrometry. Poly (ADP-ribose) polymerase-1 (PARP-1), which catalyzes polyADP-ribosylation, was newly identified as a CHFR interacting protein. CHFR promoted polyubiquitination of PARP-1. Conversely, PARP-1 poly(ADP-ribosyl)ated CHFR. In addition, we mapped the region of both CHFR and PARP-1 required for the interaction. Because CHFR delays entry into metaphase in response to mitotic stress, we investigated whether PARP-1 is involved in the mitotic checkpoint. In the presence of PARP-1, CHFR arrested the cell cycle. On the other hand, in the absence of PARP-1, CHFR had no effect on the cell cycle arrest. Additionally, we found the knockdown of PARP-1 resulted in cell cycle arrest itself. As overexpression of PARP-1 has been reported in several human tumors, our findings suggest the functional relationships between CHFR and PARP-1 could play an important role in regulation of cell cycle and tumor suppression. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research; 2011 Apr 2-6; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2011;71(8 Suppl):Abstract nr 2968. doi:10.1158/1538-7445.AM2011-2968
AB0849 Retention rate of adalimumab, etanercept and infliximab at 5 years in patients with ankylosing spondylitis: Report from the rhumadata computerized database
Authors: D. Choquette, D. Sauvageau, J.-P. Raynauld
Journal: Annals of the Rheumatic Diseases (2013)

<h3>Background</h3> Most of the data exploring the recent development of the treatment of ankylosing spondylitis come from randomized placebo controlled phase III trials. The patients who are randomized in these trial are typically very different from those that we see and treat in our daily clinical practice. The data coming from these trial is also usually for the short term, maximally one to two years. At the Institute of Rheumatology of Montreal, we have been collecting data of patients suffering from ankylosing spondylitis using a locally developed software named Rhumadata. The software permits data collection directly from patients as well those from the healthcare practitionners (Nurses, Physicians, etc) <h3>Objectives</h3> The primary objective of this study is to evaluate the retention rate of patients suffering from ankylosing spondylitis after 5 years of exposure to either adalimumab (ADA), etanercept (ETA)or infliximab (INF). The secondary objective is to evaluate if all patients exposed to each biologic agents are similar or if there are characteritics that are different at entry between adalimumab, etanercept and infliximab <h3>Methods</h3> Using the Rhumadata software, we extracted all patients suffering from ankylosing spondylitis as diagnosed by his rheumatologist.These patients had to be exposed to either adalimumab, etanercept or infliximab as first exposure ever to a biologic agent. Data extraction period ranges from 2005 up to 2011. All patients had to exposed to at least two different NSAIDS for a minimum of three months each to be eligible to received an anti-TNF agents. Their baseline BASDAI had to be equal or superior to 4 at entry. The different variables extracted from Rhumadata for each cohorts are: Number of patients, duration of disease, age at the time of anti-TNF introduction, gender, HLA-B27 status, morning stiffness duration, VAS pain evaluation, BASDAI and BASFI. <h3>Results</h3> 119 patients suffering from ankylosing spodylitis and exposed to either ADA, ETA or INF were found and extracted from the Database. 53 patients were prescribed ADA, 18 ETA and 48 INF. More than 75% of patients of each cohort were of male gender and the Mean age is 46 (SD 11). No significant differences in demographics and clinical variables were found between each group at baseline (T-test). Proportion of patients remaining on the same anti-TNF agent at 1 year is 80%, 2 years 70% and 5 years 55% (p=.988) (Kaplan-meier analysis). <h3>Conclusions</h3> Adalimumab, etanercept and infliximab retention rates at 1, 2 and 5 years for patients with ankylosing spondylitis are similar. Each of these agent is a adequate option in the treatment of ankylosing spondylitis. <h3>Disclosure of Interest</h3> None Declared
Cancer Data Bases Expanding
Authors: T. Reynolds
Journal: JNCI Journal of the National Cancer Institute (1992)

Journal Article Cancer Data Bases Expanding Get access Tom Reynolds Tom Reynolds Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 84, Issue 11, 3 June 1992, Pages 839–841, https://doi.org/10.1093/jnci/84.11.839 Published: 03 June 1992
Abstract P5-10-20: Breast Cancer Multi Disciplinary Team (MDT)Adjuvant Chemotherapy Decision: Impact of Adjuvant! Online Estimates of 10-Year Risk of Death and Chemotherapy Benefit on the Decision Making Process
Authors: A Balakrishnan, S Haysom, L Rivett, A Austin, D. Ravichandran
Journal: Cancer Research (2010)

Abstract Introduction: Breast cancer patients in the UK National Health Service (NHS) are cared for by breast cancer multidisciplinary teams (MDT). The wide range of knowledge and experience available in MDT produce a collective expert opinion on the management strategy for individual patients. Adjuvant! Online is an online computer programme that makes quantitative estimates of the effect of adjuvant chemotherapy (CT) on the 10-year risk of death and relapse. We studied whether the Adjuvant! Online produced numerical estimates would influence the adjuvant CT decision making of a breast cancer MDT. Methods and Materials: We prospectively monitored a breast cancer MDT for a period of 12 months. Once the MDT had finished discussing a patient and adjuvant therapy decisions were made, Adjuvant! Online produced 10-year risk of breast cancer related death and the reduction of this risk that may be achieved by adjuvant CT were presented to the MDT. Any change to the original MDT recommendations as a result of this information was recorded. Results: 109 post-operative early breast cancer patients that were suitable for input into Adjuvant! Online discussed in 41 MDT's were included in the study. Adjuvant therapy decisions included chemotherapy (n=56), radiotherapy (n=96) and endocrine therapy (n=89). The numerical estimates from Adjuvant! Online only changed the management of one patient, by showing a marginal (3.8%) survival benefit with CT that made the MDT offer chemotherapy to this patient where the original decision was not to. Conclusions: Most adjuvant therapy decisions are easy to make without the need for numerical estimates of benefit when the MDT's are staffed by experienced breast cancer clinicians. Regular use of Adjuvant! Online or similar aids may not be necessary during the MDT discussion. These could be used on a selective basis where there is difficulty reaching a consensus. Citation Information: Cancer Res 2010;70(24 Suppl):Abstract nr P5-10-20.
1261 DELETION OF CASPASE-8 IN HEPATOCYTES IMPROVES HEPATIC INFLAMMATION AND INJURY BY MODULATING THE EXPRESSION OF LIVER METABOLISM-RELATED GENES IN A MURINE MODEL OF NASH
Authors: M. Hatting, F.J. Cubero, Z. Gang, F. Schumacher, G. Sellge, N. Gassler, M. Boekschoten, M. Mueller, C. Liedtke, C. Trautwein
Journal: Journal of Hepatology (2013)
A memorable patient: The go ahead from Jung
Authors: C L Davidson
Journal: BMJ (1998)

Meningiomas are always memorable, being among the few cerebral tumours with an excellent prognosis. At the time of my retirement in 1975 I was able to remember the clinical details of each one of my three patients who had had this diagnosis. The most unforgettable was the first, way back in the early 1950s.

A middle aged man comfortably off in the Bradford wool trade, he had gradually developed a left hemiparesis, and, while there were no other diagnostic features, it seemed likely …
REPORT CVIII. SOME POINTS ON THE EXPERIMENTAL PRODUCTION AND CONTROL OF THE VASCULAR ATONY OF SURGICAL SHOCK
Authors: P. L. Mummery, W. L. Symes
Journal: BMJ (1908)

almost cheerful.Respirations 30.The dressing was soaked with black "coffee grounds" material mixed with gastric secretion and mucus.Both tubes were flushed out with
CMRL-T, a novel T-cell line showing asynchronous phenotype (CD34+/CD1a−/TCRαβ+) and dual T-cell receptor β chain
Authors: R Di Noto, P Mirabelli, E Mariotti, L Sacchetti, F Pane, B Rotoli, C Lo Pardo, L Del Vecchio, C Mecucci, F Salvatore
Journal: Leukemia (2006)
Smallpox Vaccination Policy — The Need for Dialogue
Authors: Anthony S. Fauci
Journal: New England Journal of Medicine (2002)

The recent cases of anthrax due to bioterrorism and the terrorist attacks of September 11, 2001, have led to an unprecedented degree of concern and urgency regarding the vulnerability of our society to more such attacks.1 At the Department of Health and Human Services, efforts to counter bioterrorism are focused on a group of pathogenic microbes that include Bacillus anthracis (the cause of anthrax), variola virus (the cause of smallpox), Yersinia pestis (the cause of plague), Francisella tularensis (the cause of tularemia), Clostridium botulinum (which causes botulism), and the hemorrhagic-fever viruses such as Ebola.1 Within this group, smallpox stands out . . .
P1-08-10: Invasive Lobular Breast Cancer – No Increased Risk of Contralateral Disease.
Authors: F Langlands, K Horgan, O Kearins, R Burns, D Dodwell
Journal: Cancer Research (2011)

Abstract Background: Invasive lobular carcinoma (ILC) is the second most common type of breast cancer accounting for up to 14% of invasive breast cancers. Worldwide the incidence of breast cancer is increasing each year. Large population based studies using the Surveillance, Epidemiology, and End results (SEER) data have shown that the incidence of ILC has increased from 1977 to 1995. ILC has historically been thought to be associated with an increased risk of developing contralateral breast cancer and this belief may, in part, be responsible for the increasing trend towards contralateral prophylactic mastectomy. Methods: All female patients diagnosed with breast cancer during the time period 1998–2003 were identified from two large cancer registries, Northern and Yorkshire Cancer Registry and Information Service (NYCRIS) and West Midlands Cancer Intelligence Unit (WMCIU). All patients diagnosed with either Infiltrating duct(adeno) carcinoma, microinvasive ductal carcinoma, infiltrating ductular carcinoma (all classified as ‘ductal') or lobular (adeno)carcinoma were included. Patients with a mixed type of breast cancer were excluded from the analysis. Follow-up was complete until October 2010. Data were compiled for diagnosed contralateral breast cancer of any histological type. Results: Of the 32,735 patients with invasive ductal cancer 898 (2.74%) developed a contralateral breast cancer. In comparison 166 (3.1%) of 5397 patients with lobular cancer developed a contralateral breast cancer. The median time to first contralateral event was equivalent for both morphologies (ductal 40 months and lobular 39 months). Conclusion: This study suggests that there is no increased risk for developing a contralateral breast cancer in patients diagnosed with an invasive lobular breast cancer. Citation Information: Cancer Res 2011;71(24 Suppl):Abstract nr P1-08-10.
Spinal Uptake Mimicking Metastasis in SPECT/CT Bone Scan in a Patient With Superior Vena Cava Obstruction
Authors: Olivier Rager, René Nkoulou, Valentina Garibotto, Sana Boudabbous, Daniel Arditi
Journal: Clinical Nuclear Medicine (2013)

A 46-year-old female patient with a mediastinal neuroendocrine carcinoma complicated by superior vena cava syndrome was referred for a bone metastatic workup. Bone scan with SPECT/CT showed several vertebral fixations without alterations on the unenhanced CT, but a CT scan with injection of contrast media showed vertebral densities matched to the lesions described on the SPECT/CT. This pattern confirmed presence of collateral paths through vertebral veins due to superior vena cava syndrome. Lack of metastases was confirmed by MRI.
P269 SHORT-TERM PERIODIC ADMINISTRATION OF MULTIPROBIOTIC FROM CHILDHOOD PREVENTS DEVELOPMENT OF NONALCOHOLIC FATTY LIVER DISEASE IN ADULT MONOSODIUM GLUTAMATE-INDUCED OBESE RATS
Authors: G. Mykhalchyshyn, T. Falalyeyeva, N. Kobyliak, O. Virchenko, T. Beregova, P. Bodnar
Journal: Journal of Hepatology (2014)
A New Ventilatory Assister for Patients with Respiratory Acidosis
Authors: Asher Marks, Jose Bocles, Loretta Morganti
Journal: New England Journal of Medicine (1963)

INADEQUATE alveolar ventilation leads to retention of carbon dioxide, with accompanying respiratory acidosis. Most patients with chronic obstructive emphysema die with this complication. The importance of infection, sedation and the incautious use of oxygen in the pathogenesis of ventilatory failure has been well described,1 2 3 4 5 6 7 8 9 10 11 and the necessity of increasing alveolar ventilation is stressed.5 , 9 10 11 12 13 14 A variety of mechanical aids and chemical stimuli are recommended.10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 The mechanical assisters in current favor in this country are the various devices for intermittent positive-pressure breathing. Several observations indicate that in patients with advanced disease, this therapy may not be successful,9 , 25 , 26 and Jones et al.26 recently . . .
FRI0320 Differencies and similarities between childhood- and adult-onset systemic lupus erythematosus in hungarian patients
Authors: T. Tarr, B. Derfalvi, N. Györi, Z. Siminszky, G. Szegedi, M. Zeher
Journal: Annals of the Rheumatic Diseases (2013)

<h3>Background</h3> Systemic lupus erythematosus (SLE) is a multifactorial autoimmune disease with highest prevalence among women of childbearing age, however, SLE can also develop in children younger than 16 years (childhood-onset lupus). <h3>Objectives</h3> In our present study, we compared the characteristics of adult- and childhood-onset SLE among Hungarian lupus patients. <h3>Methods</h3> We created a Hungarian national register of childhood onset of SLE. We collected the clinical and laboratory parameters, the treatments and survivals of 79 child patients from six different rheumatology/immunlogy centres and compared them with the data of 342 adult onset lupus patients registered in the Clicical Immunolology Department, University of Debrecen. <h3>Results</h3> We found the same female to male ratio in the two groups (10:1.3vs. 10:0.89). Significantly higher prevalences of nephritis (43% vs. 26,4% p&lt;0,0001, RR:1.81), hematologic manifestations (57% vs. 36.65%, p: 0.0013, RR:1.96), butterfly rash (61% vs. 35,5% p&lt;0,0001, RR:5.615) oral ulcers (11% vs. 4, 11%, p:0,0229, RR:2.225)were found among patients with pediatric lupus. In contrary, neurological symptoms (30%vs. 6%, p&lt;0,0001) and polyarthritis (87 % vs 68 % p:0,0002) were significantly more frequent among adult onset of patients with SLE. Anti-cardiolipin (46% vs. 24%, p:0.0044), anti-beta II glikoprotein I (30.1 % vs 12.7 % p:0,0011), anti SSA (40.9% vs. 24%, p:0,0066) and anti-SSB (45.6 % vs. 15.2% p&lt;0,0001) autoantibodies appeared significantly higher prevalence in adult lupus patients. Treatments of the children were the same, but they received high dose intravenous immunglobulin and mycophenlate mophetil more often than the adults. We did not find any differences between the survival of pediatric and adult onset lupus patients. <h3>Conclusions</h3> The results of this study show that some clinical manifestations and serological findings of lupus are different in childhood-onset SLE and adult-onset SLE, but the outcome of the disease is not different in Hungarian adult and pediatric patients with lupus. <b>Disclosure of Interest</b>: None Declared
A New Safer and More Effective Triphenylethylene Antiestrogen (SS1020) for the Treatment and Prevention of Breast Cancer.
Authors: S. Shibutani, Y. Okamoto, N. Suzuki, X. Liu, H. Kim, Y. Laxmi
Journal: Cancer Research (2009)

Abstract Background: Tamoxifen (TAM) is widely used as a first-line endocrine therapy for breast cancer patients and as a prophylactic agent for women at high risk of developing this disease. Besides the significant benefit, long-term administration of TAM has serious side effects, including endometrial cancer. These side-effects are due to the DNA damaging and/or estrogenic action of the drug. Raloxifene (RAL) approved as a chemopreventive agent for postmenopausal women at high risk for invasive breast cancer retains an estrogenic action. RAL has a poor bioavailability. This makes it difficult to achieve adequate bioavailability by oral administration in humans. High doses are required to obtain an efficacy quivalent to that achieved with TAM. Several other antiestrogens were dropped out from the clinical trials due to their undesirable effects on the uterus. Therefore, development of new antiestrogen alternatives, but free of genotoxic and estrogenic potential, having significant antitumor potential beyond TAM and RAL is urgently required for breast cancer therapy and prevention.Results: SS1020 was developed as a new triphenylethylene antiestrogen in our laboratory. Although TAM is a hepatic carcinogen and produces a high level of DNA damage in rats, SS1020 did not produce such DNA damage. Unlike TAM and RAL, SS1020 had no detectable uterotrophic activity in OVX-rats even treated with a high dose (10 mg/kg). These indicate that SS1020 is free of genotoxic and estrogenic activities. The antitumor potential of SS1020 against 7,12-dimethyl-benz(a)anthracene (DMBA)-induced mammary carcinoma in rats and human MCF-7 breast cancer xenograft in athymic nude mice was superior to that of TAM and RAL. In addition, the development of estrogen-induced mammary tumor in rats was completed inhibited by dietary intake of SS1020, indicating that this compound has preventive potential. The bioavailability of SS1020 was approximately 35 times higher than that of RAL. The maximum blood concentration (493 ng/ml serum) of SS1020 was observed at 2 hour after the oral treatment while that of RAL (15.6 ng/ml) was at 6 hours, indicating that SS1020 is absorbed rapidly into the body. SS1020 has a much higher bioavailability than RAL, endowing it with higher antitumor potential than RAL.Conclusion: Taken together, SS1020 lacking genotoxic and estrogenic actions has anti-breast cancer activity superior to that of TAM and RAL and has a preventive potential. SS1020 is a safer and more effective antiestrogen candidate for breast cancer therapy and prevention. Citation Information: Cancer Res 2009;69(24 Suppl):Abstract nr 4085.
Efficacité de la pose endoscopique de prothèse colique métallique couverte dans le traitement des sténoses coliques bénignes
Authors: G Vanbiervliet, P Bichard, E Ben Soussan, K Barange, JM Canard, H Lamouliatte, JC Saurin
Journal: Endoscopy (2011)

Introduction: Le but de l'étude a été d'évaluer l'efficacité de la pose endoscopique de prothèse métallique complètement couverte dans le traitement des sténoses bénignes coliques.
The Detection of Vesicoureteral Reflux in the Nonfunctioning Lower Half of an ‘Occult’ Duplex Kidney by Tc-99m MAG3 Indirect Radionuclide Cystography
Authors: Diego De Palma, Gian Antonio Manzoni
Journal: Clinical Nuclear Medicine (2000)

A 6-year-old child underwent a Tc-99m MAG3 dynamic renal scan because of recurrent urinary tract infection. An ultrasound performed 2 weeks before revealed only a right-side hydronephrosis. The summed early image showed a right kidney that seemed to be cut in half. Imaging during voiding showed reflux in the right pelvicalyceal system. The composite image formed with superimposition of these two frames clearly showed that the reflux affected a functionally excluded lower half of a kidney with unknown complete duplication of the collecting system.